# A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

> **NCT02443337** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 31 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** LY3023414
- **DRUG:** Necitumumab

## Key facts

- **NCT ID:** NCT02443337
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** The study stopped due to lack of efficacy.
- **Last updated:** 2020-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443337, "A Study of LY3023414 and Necitumumab in Squamous Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02443337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*